Unknown

Dataset Information

0

Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation.

ABSTRACT: Factor Xa (FXa) plays a significant role in the blood coagulation cascade and it has become a promising target for anticoagulation drugs. Three oral direct FXa inhibitors have been approved by the FDA for treating thrombotic diseases. By structure-activity relationship (SAR) analysis upon these FXa inhibitors, a series of novel anthranilamide-based FXa inhibitors were designed and synthesized. According to our study, compounds 1a, 1g and 1s displayed evident FXa inhibitory activity and excellent selectivity over thrombin in in vitro inhibition activities studies. Compounds 1g and 1s also exhibited pronounced anticoagulant activities in in vitro anticoagulant activity studies.

SUBMITTER: Wang W 

PROVIDER: S-EPMC6274369 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation.

Wang Wenzhi W   Yuan Jing J   Fu Xiaoli X   Meng Fancui F   Zhang Shijun S   Xu Weiren W   Xu Yongnan Y   Huang Changjiang C  

Molecules (Basel, Switzerland) 20160414 4

Factor Xa (FXa) plays a significant role in the blood coagulation cascade and it has become a promising target for anticoagulation drugs. Three oral direct FXa inhibitors have been approved by the FDA for treating thrombotic diseases. By structure-activity relationship (SAR) analysis upon these FXa inhibitors, a series of novel anthranilamide-based FXa inhibitors were designed and synthesized. According to our study, compounds 1a, 1g and 1s displayed evident FXa inhibitory activity and excellent  ...[more]

Similar Datasets

Unknown Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors.
| S-EPMC5514901 | biostudies-literature
Unknown Innovative Three-Step Microwave-Promoted Synthesis of N-Propargyltetrahydroquinoline and 1,2,3-Triazole Derivatives as a Potential Factor Xa (FXa) Inhibitors: Drug Design, Synthesis, and Biological Evaluation.
| S-EPMC7037264 | biostudies-literature
Unknown Structure-based design, synthesis, and biological evaluation of novel pyrimidinone derivatives as PDE9 inhibitors.
| S-EPMC6089849 | biostudies-literature
Unknown Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Amine-based Histone Deacetylase Inhibitors.
| S-EPMC5881582 | biostudies-literature
Unknown Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors.
| S-EPMC6651501 | biostudies-literature
Unknown Structure-Based Design, Synthesis, and Biological Evaluation of Triazole-Based smHDAC8 Inhibitors.
| S-EPMC7187165 | biostudies-literature
Unknown Design, Synthesis, and Biological Evaluation of Novel Thienopyrimidine Derivatives as PI3K? Inhibitors.
| S-EPMC6804295 | biostudies-literature
Unknown Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR.
| S-EPMC4027470 | biostudies-literature
Unknown Design, Synthesis, and Biological Evaluation of Novel Allosteric Protein Disulfide Isomerase Inhibitors.
| S-EPMC8276234 | biostudies-literature
Unknown Structure-Based Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel PDE10 Inhibitors With Antioxidant Activities.
| S-EPMC5962708 | biostudies-literature